Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
Status:
Active, not recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the effectiveness of a drug called temsirolimus in
combination with a drug called perifosine in treating brain tumors that have continued to
grow after previous treatment. Temsirolimus is an intravenous drug approved by the FDA for
treatment of other cancers (kidney cancer, certain types of lymphoma) but not for brain
tumors. Perifosine is a pill that has not been approved by the FDA which blocks a messenger
that tells cancer cells to grow. Research suggests that combined treatment with both drugs is
better than either alone, and that it is reasonably safe.